News & Updates
Filter by Specialty:
Dabrafenib plus trametinib boasts high pathological response for stage III melanoma
Pathological response rates are high for neoadjuvant dabrafenib plus trametinib among patients with stage III melanoma, but recurrence-free survival (RFS) rates are low, reports a study.
Dabrafenib plus trametinib boasts high pathological response for stage III melanoma
12 Aug 2024
First-line nivolumab-ipilimumab improves life quality, eases symptoms in metastatic CRC
First-line treatment with nivolumab (NIVO) in combination with ipilimumab (IPI) results in better health-related quality of life (HRQOL) and fewer symptoms, when compared with chemotherapy, in patients with centrally confirmed microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), as shown in the CheckMate 8HW study presented at ESMO GI 2024.
First-line nivolumab-ipilimumab improves life quality, eases symptoms in metastatic CRC
12 Aug 2024
Cabozantinib offers survival benefits to ICI-treated HCC patients
A phase II trial of cabozantinib demonstrates the study drug’s efficacy in patients with hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitor (ICI) regimens.
